NORDIC NANOVECTOR – CHANGE IN THE BOARD OF DIRECTORS

Report this content

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY IN OR INTO THE UNITED STATES, CANADA, JAPAN OR AUSTRALIA OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE IMPORTANT INFORMATION AT THE END OF THE ANNOUNCEMENT.

Oslo, 9 March 2015. Reference is made to the announcement made earlier today regarding the resolutions made by 2015 Annual General Meeting in Nordic Nanovector ASA (the “Company”). As resolved by the Annual General Meeting, the Company’s Board of Directors (the “Board”) will with effect from 12 March 2015 consist of the following: Ludvik Sandnes (Chairman), Per Samuelsson, Roy Hartvig Larsen, Hilde H. Steineger and Gisela M. Schwab.
Alexandra Morris is by law prevented from being a board member in a listed company due to her position as a portfolio manager at Odin Fund Management and she was thus not available for re-election.
“We are grateful for and would like to thank Alexandra for her commitment and contribution as a member of the Board and Board committees. Alexandra’s contribution, support and insight have been highly appreciated and we will miss her on the Board”, says Ludvik Sandnes, Chairman of the Board.

Alexandra Morris is being replaced by Gisela M. Schwab. “I look forward to joining the accomplished Board of Nordic Nanovector. The Company’s innovative targeted radioimmunotherapy technology holds promise for patients with cancer, and the lead compound BetalutinTM has already shown encouraging results in early clinical development", says Gisela Schwab, MD.

Gisela M. Schwab, M.D., has served as Executive Vice President and Chief Medical Officer since January 2008 of Exelixis, Inc. She joined Exelixis in 2006 as Senior Vice President and Chief Medical Officer. From 2002 to 2006, she held the position of Senior Vice President and Chief Medical Officer at Abgenix, Inc., a human antibody-based drug development company. She also served as Vice President, Clinical Development at Abgenix from 1999 to 2001. Prior to working at Abgenix, from 1992 to 1999, she held positions of increasing responsibility at Amgen Inc., most recently as Director of Clinical Research and Haematology/OncologyTherapeutic Area Team Leader. From August 2011 to July 2014 Dr. Schwab has served as a member of the board of directors of Topotarget A/S, a publicly-held biopharmaceutical company. Since June 2012 she has served as a member of the board of directors of Cellerant Therapeutics, Inc. a privately held biopharmaceutical company. She received her Doctor of Medicine degree from the University of Heidelberg, trained at the University of Erlangen-Nuremberg and the National Cancer Institute, Bethesda Maryland, USA, and is board certified in internal medicine and haematology and oncology. She is a German citizen, and resides in the U.S.

“We are excited to have Gisela Schwab join the Board and believe that her long-standing experience within the field of oncology and drug development will greatly benefit the Company going forward”, says Ludvik Sandnes, Chairman of the Board.

For further queries, please contact:
Luigi Costa, CEO
Cell: (41) 79 124 8601
Fax: (47) 22 58 00 07
E-mail: lcosta@nordicnanovector.com

Tone Kvåle, CFO
Cell: (47) 91 51 95 76
Fax: (47) 22 58 00 07
E-mail: tkvale@nordicnanovector.com

IMPORTANT INFORMATION

United States

These materials may not be published, distributed or transmitted in the United States, Canada, Australia or Japan. These materials do not constitute an offer of securities for sale or a solicitation of an offer to purchase securities (the “Shares”) of Nordic Nanovector ASA (the “Company”) in the United States, Norway or any other jurisdiction. The Shares of the Company may not be offered or sold in the United States absent registration or an exemption from registration under the U.S. Securities Act of 1933, as amended (the “U.S. Securities Act”). The Shares of the Company have not been, and will not be, registered under the U.S. Securities Act. Any sale in the United States of the securities mentioned in this communication will be made solely to “qualified institutional buyers” as defined in Rule 144A under the U.S. Securities Act.

European Economic Area

Any offering of securities will be made by means of a prospectus to be published that may be obtained from the issuer or selling security holder, once published, and that will contain detailed information about the Company and its management, as well as financial statements.

These materials are an advertisement and not a prospectus for the purposes of Directive 2003/71/EC, as amended (together with any applicable implementing measures in any Member State, the “Prospectus Directive”). Investors should not subscribe for any securities referred to in these materials except on the basis of information contained in the prospectus.

In any EEA Member State other than Norway (from the time the prospectus has been approved by the Financial Supervisory Authority of Norway, in its capacity as the competent authority in Norway, and published in accordance with the Prospectus Directive as implemented in Norway) that has implemented the Prospectus Directive, this communication is only addressed to and is only directed at “qualified investors” in that Member State within the meaning of Article 2(1)(e) of the Prospectus Directive (“Qualified Investors”), i.e., only to investors to whom an offer of securities may be made without the requirement for the Company to publish a prospectus pursuant to Article 3 of the Prospectus Directive in such EEA Member State.

United Kingdom

In the United Kingdom, these materials are only being distributed to and are only directed at Qualified Investors who (i) are investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended) (the “Order”) or (ii) are persons falling within Article 49(2)(a) to (d) of the Order (high net worth companies, unincorporated associations, etc.) (all such persons together being referred to as “Relevant Persons”). These materials are directed only at Relevant Persons and must not be acted on or relied on by persons who are not Relevant Persons. Any investment or investment activity to which this document relates is available only to Relevant Persons and will be engaged in only with Relevant Persons.

Luigi Costa, CEO
Cell:    (41) 79 124 8601 
Fax:    (47) 22 58 00 07
E-mail: lcosta@nordicnanovector.com

Tone Kvåle, CFO
Cell:    (47) 91 51 95 76
Fax:    (47) 22 58 00 07
E-mail: tkvale@nordicnanovector.com

About Nordic Nanovector

Nordic Nanovector is a biotech company focusing on the development and commercialization of novel targeted therapeutics in haematology and oncology. The Company’s lead clinical-stage product opportunity is Betalutin™, the first in a new class of Antibody-Radio-Conjugates (ARCs), designed to improve upon and complement current options for the treatment of Non-Hodgkin’s Lymphoma (NHL). NHL is an indication with substantial unmet medical need and orphan drug opportunities, representing a growing market worth over $12 billion by 2018.

Betalutin™ comprises a tumor-seeking anti-CD37 antibody conjugated to low intensity radionuclide (Lutetium 177). It has shown promising efficacy in Phase 1 studies in a difficult-to-treat NHL patient population and as well as a very favourable tolerability. Betalutin™ is fast advancing through clinical development and with first approval anticipated in 2018.

Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialization of Betalutin™ in core markets, while exploring potential distribution agreements in selected geographies. The Company is committed to developing its ARC pipeline to treat a number of select cancer indications.

www.nordicnanovector.com


Tags:

Subscribe